source
- Camurus receives second complete response letter for acromegaly drug CAM2029; Teva announces workforce reductionsCamurus reported that the FDA issued a second complete response letter for its investigational acromegaly therapy CAM2029, citing issues related to a third‑party manufacturer. The agency’s concern…
- Some U.S. Employers Plan to End GLP-1 Obesity Drug Coverage in 2027, Even as Prices FallA Reuters report says roughly 10% of U.S. employers that currently cover GLP-1 medicines for weight loss intend to stop covering them in 2027. The move comes as enrollment in obesity-treating drugs…